Quick search:
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 The Many Shades of KRAS: Investigators Seek to Exploit Heterogeneity in Mutations
2 5 Things to Know About Targeting Mutant KRAS in Pancreatic Cancer
3 Lung Cancer Cells Have Differential Signaling Responses to KRAS Inhibitor Treatment with Important Implications for Emerging Clinical Trials
4 FDA Grants Sotorasib a Priority Review for KRAS G12C+ Advanced NSCLC
5 Genetic Testing in KRAS- and EGFR-Mutant Lung Cancers
6 FDA Grants Priority Review to Sotorasib to Treat Patients With KRAS G12C–Mutated NSCLC
7 Global KRAS Inhibitors Drug Market Sales Size Opportunity Clinical Development To Surpass USD 1 Billion By 2025
8 Mirati and MD Anderson team up on KRAS; Sanofi inks deal with a Harvard spinout for oral biologics
9 Lung cancer cells activate different signaling pathways in response to KRAS inhibitors
10 Global KRAS Inhibitors Market Opportunity & Clinical Trials Outlook 2025: A $1 Billion Market Opportunity
11 Elicio Therapeutics Sharpens Development Plan for Cancer Vaccine in KRAS-Mutated Tumors
12 The epic battle with cancer's 'Death Star'
13 Global KRAS Inhibitor Drug Market Size Forecast Clinical Trials Development Companies Report 2025 |
14 Mirati Therapeutics, MD Anderson Partner to Develop Drugs for KRAS-Mutant Cancers
15 Pew-Stewart Scholars Uncover New Strategies to Target Cancer
16 KRAS drugs may do best in tough subtype
17 A Phase I Study of MRTX849 and TNO155 in Advanced Cancers with the KRAS G12C Genetic Mutation
18 Using natural compounds to target KRAS mutated non-small cell lung cancer
19 Elicio Therapeutics Announces FDA Clearance of IND Application for ELI-002 -- A Therapeutic Vaccine Targeting Mutated KRAS Cancers
20 Croatia's Kras 2020 cons net profit up 32%
21 Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database.
22 Dr. Li on the Efficacy of Sotorasib in KRAS+ Advanced NSCLC
23 Deaths March 3, 2021: Eugene Casimir Kras – West of the I
24 Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
25 CURE: New Drug Shows Promise for People with Subset of Non-Small Cell Lung Cancer
26 Targeting a Mutated KRAS Gene to Treat a Variety of Solid... : Oncology Times
27 Promising Results from the First-Ever Trial of a Drug that Blocks Cancer Gene KRAS
28 At ESMO TAT meeting, translating translation inhibition
29 Inhibitor of KRAS gene mutation shows promise in lung, bowel and other solid tumors
30 Targeting KRAS-Mutant Tumors With Indirect Targeting of Related Pathways Yields Hope in Solid Tumors
31 KRAS Now a Druggable Target in Non–Small Cell Lung Cancer
32 KRAS Inhibitors Show Promise in Early Studies
33 KRAS Makes Strides Toward Becoming “Druggable” in GI Cancers in 2020
34 KRAS Inhibitor Continues to Impress in NSCLC
35 Amgen guns for speedy KRAS cancer approval as it leads race
36 McKesson-led Consortium to Establish Best Practices for Lung Cancer Molecular Testing, Treatment
37 Amgen study data bolster prospects of KRAS-blocking cancer drug
38 Amgen files KRAS trailblazer sotorasib with FDA for lung cancer
39 One Step at a Time — Clinical Evidence That KRAS Is Indeed Druggable | NEJM
40 Cardiff Oncology to Present at HC Wainwright Global Life Sciences Conference
41 KRAS inhibitor and lung cancer
42 Global Kirsten Rat Sarcoma (KRAS) Market Analysis, Size, Share, Growth, Trends And Forecast 2027 ||Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV – The Courier
43 Delivering on a Promise: The Present and Future of Targeted Protein Degradation
44 WellmarkerBio receives approval for Phase I clinical trial from the Australian Therapeutic Goods Administration
45 FDA Grants Breakthrough Therapy Designation to Sotorasib for NSCLC with KRAS G12C Mutation
46 Genotype-directed therapies for lung cancer
47 Eli Lilly crashes out of KRAS race as toxicity sees it ditch phase 1 effort
48 Sotorasib confers durable clinical benefit in KRAS G12C-mutated NSCLC
49 Clinically Meaningful Benefit in Advanced KRAS G12C+ NSCLC Is Seen With Sotorasib
50 Mirati's KRAS drug shrinks 45% of NSCLC tumors, putting it in Amgen's slipstream on race to FDA
51 Assessing the Actionability of KRAS Mutations in NSCLC
52 Amgen's KRAS-blocking drug proves effective for lung cancer patients
53 Adagrasib Shows Promise in Phase 1/2 Trial for KRAS G12C Mutated NSCLC, CRC, and Other Solid Tumors
54 Anti-KRAS for NSCLC, CRC; Do Heart Meds Boost Cancer Tx?
55 Five Prime's lesson in never giving up
56 World Lung 2020 – no advance on Amgen’s “consistent” Kras promise
57 Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
58 Amgen readies KRAS-blocking cancer drug for FDA filing
59 CRUK scientists develop drug that targets KRAS pathways
60 Pursuing Improved Survival With KRAS, PARP Inhibitors and Metabolic Agents in Pancreatic Cancer
61 A KRAS drug is likely coming — fast — as the FDA points Amgen's frontrunner to a looming finish line
62 Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program
63 Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib
64 Amgen files KRAS inhibitor sotorasib with EMA
65 Agilent to Acquire Resolution Bioscience for up to $695M, Expanding in Precision Medicine
66 Sotorasib shows anticancer activity in KRAS G12C-mutated NSCLC
67 The First Targeted Therapy For Lung Cancer Patients With The KRAS Gene Mutation–Extraordinary Results With Sotorasib
68 Amgen teases 'promising' phase 2 data for closely watched KRAS prospect
69 Mirati results set new response bar for KRAS-blocking lung cancer drugs
70 Adagrasib Shows Early Efficacy in KRAS G12C-Mutant NSCLC and CRC
71 KRAS G12C Emerges as New Target in Lung Cancer
72 Chasing Amgen on KRAS combo, Roche dishes out $75M for Relay's SHP2 drug to pair with in-house program
73 Global KRAS Inhibitor Drug Market Sales Size Clinical Trials Forecast Report 2026
74 Adagrasib Shows Promising Activity in KRAS G12C+ NSCLC, CRC, and Other Solid Tumors
75 Inhibitor of Cancer-Causing KRAS Gene Mutation Shrinks Tumors and is Well-Tolerated
76 Worldwide Indsutry for KRAS Inhibitors to 2025
77 Amgen's KRAS Inhibitor Sotorasib Effective in Non-Small Cell Lung Cancer
78 KRAS Positive Lung Cancer: Testing and Management
79 CodeBreaK Update Shows Durable Antitumor Activity With Sotorasib In KRAS-Mutant NSCLC
80 FDA Approval Sought for Sotorasib for KRAS G12C–Mutated Advanced or Metastatic NSCLC
81 Why KRAS Inhibitors for Lung Cancer Stop Working (and What Can Be Done about It)
82 Revolution Medicines Expands Development of SHP2 Inhibitor in KRAS-Mutated Cancers
83 KRAS May Predict Benefit of MEK Inhibitors in Some Ovarian Cancers
84 Dr. Ou on Investigational KRAS Inhibitors in Lung Cancer
85 Onvansertib Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutated mCRC
86 Sotorasib Displays Disease Control, Safety in KRAS G12C–Mutant Gastrointestinal Cancers
87 Drugging the undruggable, improbable new targets for lung cancer therapy
88 CNIO researchers develop an effective strategy against KRAS mutant lung tumors in mice
89 Conquering cancer's infamous KRAS mutation
90 Stronger together? Boehringer and Mirati team to put first KRAS-KRAS combo in the clinic
91 Triple meeting – Mirati needs Kras responses to hold steady
92 Turning Point Therapeutics' Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models
93 Amgen (AMGN) Files for KRAS Inhibitor for Lung Cancer in Europe
94 Global KRAS Inhibitors Market to 2025
95 How Scientists Shot Down Cancer’s ‘Death Star’
96 Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis
97 Clinical Activity of RAF/MEK + FAK Combo in KRAS-Mutant... : Oncology Times
98 Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor
99 Study shows how mutant KRAS initiates pancreatic cancer
100 Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer